Innovation-Driven Growth:
Regulatory milestones include FDA 510(k) clearance for the eVO2peak Module alongside multiple FDA‑cleared algorithms, signaling validated advancements in the product suite. AI analytics and quality certifications (ISO 13485/MDSAP) are positioned to support wider clinical and commercial deployment.
Investor Backing & Capital Strength:
The March 2025 acquisition by Kardigan is presented as integrating Prolaio into a larger heart‑health platform that expands resources, customers, and reach. Being a Kardigan subsidiary with platform‑level integration into cardiovascular trials indicates ongoing backing for scale.
Market Expansion:
Operations are cited across 20+ countries with indications of further expansion, reflecting a widening footprint and maturing deployment. The combined Prolaio–Kardigan platform is positioned to reach more patients, researchers, and biopharma partners globally.
